This study is aimed to assess the correct real-world use of a safety syringe for the repeat
self-administration of mepolizumab SC. This Phase III study will be an open-label,
single-arm, repeat-dose, multi-centre study of mepolizumab liquid drug product in a safety
syringe (100 milligrams [mg]) administered subcutaneously (SC) every 4 weeks (3 doses) in
subjects with severe eosinophilic asthma. Subjects will receive 100 mg mepolizumab SC as a
single injection that is self-administered in the thigh, abdomen or administered in the upper
arm (caregiver only). Each subject will participate in the study for up to 18 weeks including
pre-screening visit, a screening visit and a 12-week treatment period which concludes with
end of study assessments (Visit 5) 4 weeks after the last dose of mepolizumab. Approximately
55 Subjects will be enrolled in the study.